Mandy Lauw: Can Reduced-Dose DOACs Be Applied to All Patients With VTE?
Mandy Lauw, Internist-hematologist at Erasmus MC, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Evidence for the efficacy and safety of doac dose-reduction for extended VTE treatment is substantial with the renove, eve and api-cat trials. But does this apply to all patients?
This short narrative review in HemaSphere Journal, written together with Marc Carrier and Saskia Middeldorp, provides some relevant insights for clinicians whether reduced-dose doacs can be uniformly applied to all patients with thrombosis and an indication for long-term anticoagulation.”
Title: Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all?
Authors: Mandy N. Lauw, Saskia Middeldorp, Marc Carrier
Read the Full Article on HemaSphere Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation
-
Nov 8, 2026, 05:34Eugene Bolotin: Thrombosis and Survival in Pancreatic Cancer